NCT07812480 · NOT YET RECRUITING
Multimodal Biomarkers in Individual With Cognitive Impairment and Dementia
This study isn't testing a drug. It's checking whether combining a blood test (GFAP), a brain MRI, and a brainwave (EEG) test can help doctors better tell apart normal aging, mild cognitive impairment, and dementia. It's an observational study in Egypt, gathering diagnostic information rather than treating anyone.
Eligibility criteria
Inclusion Criteria: 1. Dementia diagnosed according to DSM -5\ with a total Mini-Mental State Examination score \< 24 (or \< 22 according to educational state), together with a Modified Mini-Mental State Examination (3MS) score \< 79 to confirm cognitive impairment. 2. Mild cognitive impairment diagnosed according to established diagnostic criteria according to DSM -5. 3. Men or women of at least 50 years of age. 4. Reliable in individual data and willing to make themselves available for the duration of the study. 5. Clear written informed consent obtained from a first-degree relative for each patient participant, and from the control participant himself/herself. Exclusion Criteria: * age below 50 years . * other neurological disorders or psychiatric disorders; previous history of stroke; metabolic disturbance; other major medical illnesses; epilepsy; inflammatory, autoimmune, or infectious disease; metallic objects in the body; craniotomy in the past. * Presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study * MRI contraindication (pacemaker, metallic implants, severe claustrophobia).
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-09-10